Vani Kodela, Sompuram Seshi R, Schaedle Anika K, Balasubramanian Anuradha, Bogen Steven A
Medical Discovery Partners LLC, Boston, Massachusetts (KV, SRS, AKS, AB, SAB), and Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Massachusetts (SAB).
J Histochem Cytochem. 2017 May;65(5):273-283. doi: 10.1369/0022155417694869. Epub 2017 Jan 1.
An important limitation in the field of immunohistochemistry (IHC) is the inability to correlate stain intensity with specific analyte concentrations. Clinical immunohistochemical tests are not described in terms of analytic response curves, namely, the analyte concentrations in a tissue sample at which an immunohistochemical stain (1) is first visible, (2) increases in proportion to the analyte concentration, and (3) ultimately approaches a maximum color intensity. Using a new immunostaining tool ( IHControls), we measured the analytic response curves of the major clinical immunohistochemical tests for human epidermal growth factor receptor type II (HER-2), estrogen receptor (ER), and progesterone receptor (PR). The IHControls comprise the analytes HER-2, ER, and PR at approximately log concentration intervals across the range of biological expression, from 100 to 1,000,000 molecules per test microbead. We stained IHControls of various concentrations using instruments, reagents, and protocols from three major IHC vendors. Stain intensity at each analyte concentration was measured, thereby generating an analytic response curve. We learned that for HER-2 and PR, there is significant variability in test results between clinical kits for samples with analyte concentrations of approximately 10 molecules/microbead. We propose that the characterization of immunostains is an important step toward standardization.
免疫组织化学(IHC)领域的一个重要局限是无法将染色强度与特定分析物浓度相关联。临床免疫组织化学检测并未按照分析反应曲线进行描述,也就是说,未描述组织样本中分析物浓度与免疫组织化学染色之间的关系,即(1)染色首次可见时的分析物浓度,(2)染色强度随分析物浓度成比例增加,以及(3)最终接近最大颜色强度时的分析物浓度。我们使用一种新的免疫染色工具(IHControls),测量了针对人表皮生长因子受体2型(HER-2)、雌激素受体(ER)和孕激素受体(PR)的主要临床免疫组织化学检测的分析反应曲线。IHControls包含HER-2、ER和PR分析物,在每个测试微珠上,其浓度范围跨越生物表达范围,以大约对数浓度间隔分布,从每微珠100到1,000,000个分子。我们使用来自三家主要免疫组织化学供应商的仪器、试剂和方案,对不同浓度的IHControls进行染色。测量每个分析物浓度下的染色强度,从而生成分析反应曲线。我们发现,对于HER-2和PR,分析物浓度约为10个分子/微珠的样本,临床试剂盒之间的检测结果存在显著差异。我们认为免疫染色特性的表征是迈向标准化的重要一步。